[go: up one dir, main page]

CR9898A - Derivados de prolinamida como moduladores del canal de sodio - Google Patents

Derivados de prolinamida como moduladores del canal de sodio

Info

Publication number
CR9898A
CR9898A CR9898A CR9898A CR9898A CR 9898 A CR9898 A CR 9898A CR 9898 A CR9898 A CR 9898A CR 9898 A CR9898 A CR 9898A CR 9898 A CR9898 A CR 9898A
Authority
CR
Costa Rica
Prior art keywords
modulators
sodium channel
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
CR9898A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR9898A publication Critical patent/CR9898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invencion provee un compuesto de formula (I): un solvato, sal, o profarmaco del mismo, util en el tratamiento de enfermedades y condiciones mediadas por la modulacion de los canales de sodio regulados por voltaje dependiente del uso.
CR9898A 2005-10-10 2008-04-18 Derivados de prolinamida como moduladores del canal de sodio CR9898A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
CR9898A true CR9898A (es) 2008-07-29

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9898A CR9898A (es) 2005-10-10 2008-04-18 Derivados de prolinamida como moduladores del canal de sodio

Country Status (20)

Country Link
US (2) US7655693B2 (es)
EP (1) EP1934177B8 (es)
JP (1) JP5139305B2 (es)
KR (1) KR101282464B1 (es)
AR (1) AR056575A1 (es)
AT (1) ATE556049T1 (es)
AU (1) AU2006301470B2 (es)
BR (1) BRPI0616944B8 (es)
CA (1) CA2625642C (es)
CR (1) CR9898A (es)
EA (1) EA015736B1 (es)
ES (1) ES2387405T3 (es)
IL (1) IL192627A0 (es)
MA (1) MA29817B1 (es)
NO (1) NO20082145L (es)
NZ (1) NZ567051A (es)
PE (1) PE20070592A1 (es)
PL (1) PL1934177T3 (es)
TW (1) TW200730494A (es)
WO (1) WO2007042239A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139307B2 (ja) * 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
EP2477964B1 (en) 2009-09-14 2015-02-11 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
AU2015223049B2 (en) 2014-02-27 2019-03-21 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
WO2016102967A1 (en) * 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JP2019537601A (ja) * 2016-11-02 2019-12-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 新規投薬レジメン
AU2018269924B2 (en) * 2017-05-19 2022-07-07 Biogen Ma Inc. Novel crystalline forms
MX2020003811A (es) * 2017-10-05 2021-01-15 Biogen Inc Proceso para preparar derivados de alfa-carboxamida pirrolidina.
SG11202002707VA (en) 2017-10-10 2020-04-29 Biogen Inc Process for preparing spiro derivatives
KR20210002472A (ko) * 2018-04-16 2021-01-08 바이오젠 엠에이 인코포레이티드 신경병증성 통증을 치료하는 방법
EA202192762A1 (ru) * 2019-04-10 2022-03-21 Байоджен Ма Инк. Способ получения производных альфа-карбоксамид пирролидина
KR20210150528A (ko) * 2019-04-10 2021-12-10 바이오젠 인크. 알파-카르복스아미드 피롤리딘 유도체 제조 방법
WO2021154631A1 (en) 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
KR20020015308A (ko) 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
EP1615895A4 (en) 2003-04-03 2007-11-07 Merck & Co Inc BIARYLSUBSTITUTED PYRAZOLE AS SODIUM CHANNEL BLOCKER
CN1805945A (zh) 2003-04-18 2006-07-19 麦克公司 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2006119390A1 (en) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US7858786B2 (en) 2005-05-04 2010-12-28 Vertex Pharmaceuticals Incoropated Pyrimidines and pyrazines useful as modulators of ion channels
EP1888549A2 (en) 2005-05-19 2008-02-20 Vertex Pharmaceuticals, Inc. Biaryls useful as modulators of ion channels
NZ565983A (en) 2005-09-09 2011-04-29 Smithkline Beecham Corp Pyridine derivatives and their use in the treatment of psychotic disorders
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
JP5139307B2 (ja) * 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
AR056575A1 (es) 2007-10-10
MA29817B1 (fr) 2008-09-01
EP1934177B8 (en) 2012-09-05
IL192627A0 (en) 2011-08-01
AU2006301470A1 (en) 2007-04-19
CA2625642C (en) 2013-12-24
EP1934177A1 (en) 2008-06-25
CA2625642A1 (en) 2007-04-19
US8153681B2 (en) 2012-04-10
US20100105754A1 (en) 2010-04-29
AU2006301470B2 (en) 2012-06-14
BRPI0616944B1 (pt) 2020-04-14
KR20080059296A (ko) 2008-06-26
ATE556049T1 (de) 2012-05-15
EP1934177B1 (en) 2012-05-02
JP5139305B2 (ja) 2013-02-06
TW200730494A (en) 2007-08-16
JP2009511519A (ja) 2009-03-19
WO2007042239A1 (en) 2007-04-19
US20080280969A1 (en) 2008-11-13
BRPI0616944A2 (pt) 2011-07-05
US7655693B2 (en) 2010-02-02
NO20082145L (no) 2008-05-07
BRPI0616944B8 (pt) 2021-05-25
ES2387405T3 (es) 2012-09-21
KR101282464B1 (ko) 2013-07-04
NZ567051A (en) 2011-03-31
EA200801054A1 (ru) 2008-08-29
EA015736B1 (ru) 2011-10-31
PL1934177T3 (pl) 2013-03-29
PE20070592A1 (es) 2007-06-23

Similar Documents

Publication Publication Date Title
CR9898A (es) Derivados de prolinamida como moduladores del canal de sodio
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
AR077252A1 (es) Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CR11470A (es) Compuestos organicos
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CR11045A (es) Mezclas activas pesticidas que comprenden compuestos de aminotiazolina
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
NO20082165L (no) Bifenylderivater som modulatorer av spenningsstyrte ionekanaler
ECSP12011625A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
ECSP066392A (es)
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
PA8796901A1 (es) Inhibidores de la interaccion entre mdm2 y p53
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
PA8792401A1 (es) Fenilendiaminas
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
TW200728258A (en) Novel compounds
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
MX2010001303A (es) Compuestos terapeuticos.
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)